BAY 59-7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 11, 2005, Pages 2479-2486

  Turpie, A G G ^a   Fisher, W D ^b   Bauer, K A ^c   Kwong, L M ^d   Irwin, M W ^e   Kalebo P ^f   Misselwitz, F ^g   Gent, M ^a  

^a HHS General Hospital   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e Bayer Inc   (Canada)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g BAYER PHARMA AG   (Germany)

Author keywords

Direct factor Xa inhibitor; Oral anticoagulant; Prophylaxis; Total knee replacement; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DIPYRIDAMOLE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBIN III; ARTHROPLASTY, REPLACEMENT, KNEE; DOUBLE-BLIND METHOD; ENOXAPARIN; HEMORRHAGE; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MORPHOLINES; THIOPHENES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 28444474155     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01602.x     Document Type: Article

References (18)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338S-400S.
2. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
3. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood 2003; 102: 811A.
4. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
5. Kalebo P, Ekman S, Lindbratt S, Eriksson BI, Pauli U, Zachrisson BE, Close P. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 1996; 76: 893-6.
6. Kalebo P, Anthmyr BA, Eriksson BI, Zachrisson BE. Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials. Acta Radiologica 1997; 38: 320-6.
7. Biello DR, Mattar AG, McKnight RC, Siegel BA. Ventilation-per-fusion studies in suspected pulmonary embolism. AJR Am J Roentgenol 1979; 133: 1033-7.
8. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288-96.
9. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6.
10. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-11.
11. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21.
12. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. New Engl J Med 2001; 345: 1305-10.
13. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, Haviernick S, Atkinson S, Bourgouin J. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67: 417-23.
14. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, Razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery - on behalf of the Razaxaban investigators. Blood 2003; 102: 15A.
15. Christiansen HM, Lassen MR, Borris LC, Sorensen JV, Rahr HB, Jorgensen LN, Jorgensen PW, Hauch O. Biologic tolerance of two different low molecular weight heparins. Semin Thromb Hemost 1991; 17: 450-4.
16. Christiansen HM, Rud-Lassen M, Borris LC, Sorensen JV, Schmidt K, Boll KL, Eiskjaer S, Nielsen BW, Lucht U. Biological tolerance of Logiparin, a low molecular weight heparin used in patients undergoing total hip replacement. Semin Thromb Hemost 1991; 17(Suppl. 2): 224-7.
17. Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 2001; 21: 108-13.
18. Eriksson BI, Borris LC, Dahl OE, Haas SK, Huisman MV, Kakkar AK, Kälebo P, Misselwitz F, Mühlhofer EM. Prevention of venous thromboembolism with an oral, direct Factor Xa inhibitor - BAY 59-7939 - in elective hip replacement: a dose-ranging study. J Thromb Haemost 2005; 3(Suppl. 1): [Abstract].